A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting

Phase 3

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Sponsor:

Takeda

Code:

NCT04779320

Conditions

Crohn's Disease (CD)

Eligibility Criteria

Sex: All

Age: 2 - 17

Healthy Volunteers: Not accepted

Interventions

Vedolizumab IV

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-02. This information was provided to ClinicalTrials.gov by Takeda on 2025-03-25.